| P50 | author | Devendra K Agrawal | Q41717375 |
| P2093 | author name string | Anna K Shure | |
| | Shannon K Quirk | |
| P2860 | cites work | Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma | Q60682608 |
| | Ipilimumab-induced immune-related renal failure--a case report. | Q64961263 |
| | Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission | Q82713952 |
| | Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma | Q85639942 |
| | Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy | Q85819001 |
| | Ipilimumab-associated Sweet syndrome in a melanoma patient | Q86087548 |
| | Ipilimumab associated hepatitis: imaging and clinicopathologic findings | Q86114165 |
| | Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 |
| | Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review | Q26999394 |
| | Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma | Q27005902 |
| | Nivolumab plus ipilimumab in advanced melanoma | Q27852310 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | Cancer statistics, 2014 | Q27861018 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network | Q28485085 |
| | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 |
| | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 |
| | Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 |
| | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 |
| | Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial | Q30407940 |
| | Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma | Q30839729 |
| | Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis | Q30843026 |
| | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 |
| | Ipilimumab and its toxicities: a multidisciplinary approach | Q33777476 |
| | Serious haematological toxicity during and after ipilimumab treatment: a case series. | Q33877109 |
| | Ipilimumab-induced autoimmune adrenalitis | Q33930839 |
| | Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial | Q34066501 |
| | Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma | Q34395229 |
| | A review of novel therapies for melanoma | Q34424764 |
| | Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 | Q34567635 |
| | Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. | Q34616628 |
| | Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma | Q34647109 |
| | Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study | Q34651347 |
| | Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 |
| | Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab | Q34664457 |
| | Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis | Q34720087 |
| | Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study | Q35102181 |
| | Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies | Q35154039 |
| | Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab | Q35289145 |
| | Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease | Q35913194 |
| | Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution | Q36069247 |
| | Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma | Q36259372 |
| | Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer | Q36299657 |
| | Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody | Q36544926 |
| | Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma | Q37163559 |
| | Infectious Colitis Associated With Ipilimumab Therapy | Q37311734 |
| | Ipilimumab in the treatment of metastatic melanoma: management of adverse events. | Q37601293 |
| | Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma | Q37641262 |
| | Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma | Q37677908 |
| | Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma | Q37810319 |
| | Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review | Q38001924 |
| | Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 |
| | Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma | Q38069413 |
| | Endocrine side effects induced by immune checkpoint inhibitors. | Q38087579 |
| | Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. | Q38095600 |
| | Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. | Q38114116 |
| | Ipilimumab granulomatous interstitial nephritis | Q38143506 |
| | Immune modulation in cancer with antibodies | Q38159801 |
| | Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma | Q38160837 |
| | Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management | Q38166382 |
| | Kidney injuries related to ipilimumab | Q38200955 |
| | Ipilimumab in patients with cancer and the management of dermatologic adverse events | Q38207274 |
| | Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab | Q38231036 |
| | Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. | Q40298916 |
| | Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis | Q40322388 |
| | Opportunistic infections in patients treated with immunotherapy for cancer | Q41813107 |
| | Ipilimumab-induced colonic perforation | Q42204610 |
| | Peripheral neuropathy associated with ipilimumab: a report of 2 cases | Q42278565 |
| | Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. | Q43103835 |
| | Ipilimumab-induced perforating colitis | Q43532238 |
| | Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma | Q44356441 |
| | Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression". | Q44861638 |
| | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. | Q45349601 |
| | Hemophilia A induced by ipilimumab | Q45874695 |
| | Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment | Q46471701 |
| | Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). | Q46572104 |
| | Ipilimumab immune-related adverse reactions: a case report | Q46777883 |
| | New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment | Q48733184 |
| | Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. | Q50626321 |
| | Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. | Q51347283 |
| | Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). | Q51738566 |
| | Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. | Q51752446 |
| | Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). | Q51800094 |
| | Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. | Q51803468 |
| | Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. | Q53010898 |
| | Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. | Q53424352 |
| | Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. | Q54763782 |
| | Ipilimumab-associated bilateral optic neuropathy | Q56896007 |
| | A case report of orbital inflammatory syndrome secondary to ipilimumab | Q56896131 |
| | Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody | Q56896949 |
| | A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis | Q56897654 |
| | Severe meningo-radiculo-neuritis associated with ipilimumab | Q56897693 |
| | Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? | Q56897964 |
| | Drug-induced graves disease from CTLA-4 receptor suppression | Q56898816 |
| | Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient | Q56898955 |
| | Anti-CTLA4 antibody-induced lupus nephritis | Q56900027 |
| | Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient | Q56900240 |
| | Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma | Q60143521 |
| P433 | issue | 5 | |
| P921 | main subject | metastatic melanoma | Q18975855 |
| P304 | page(s) | 412-424 | |
| P577 | publication date | 2015-06-11 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma | |
| P478 | volume | 166 | |